Betta Pharmaceuticals Co.,Ltd. (300558.SZ) released its 2025 interim report, showing operating revenue of 17.31 billion yuan, representing a year-on-year increase of 15.37%. Net profit attributable to shareholders of the listed company was 140 million yuan, a decrease of 37.53% compared to the same period last year. Net profit attributable to shareholders excluding non-recurring gains and losses reached 191 million yuan, down 11.97% year-on-year. Basic earnings per share stood at 0.33 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments